Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | N/A | -11.24% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.94 | N/A | -11.24% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and their impact on performance. They are focusing on internal improvements but did not provide specific guidance.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
No specific updates on product pipeline were provided.
The earnings report indicates that Crinetics Pharmaceuticals is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 3.89% in response to the disappointing results and lack of guidance. Investors may be cautious as the company navigates its current situation without clear direction for the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VIATRIS INC
Aug 7, 2023